Quince Therapeutics, Inc.

NasdaqGS:QNCX Stock Report

Market Cap: US$14.8m

Quince Therapeutics Past Earnings Performance

Past criteria checks 0/6

Quince Therapeutics has been growing earnings at an average annual rate of 12.5%, while the Biotechs industry saw earnings growing at 36.2% annually.

Key information

12.51%

Earnings growth rate

25.64%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth raten/a
Return on equity-210.80%
Net Marginn/a
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Analysis Article • Jan 21

Is Quince Therapeutics (NASDAQ:QNCX) Using Debt Sensibly?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Seeking Alpha • Jan 12

Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential

Summary Quince Therapeutics is rated Buy ahead of its pivotal Phase 3 NEAT trial readout in Ataxia-Telangiectasia (A-T) expected mid-Q1 2026. eDSP, QNCX's lead asset, offers chronic corticosteroid delivery with reduced toxicity, targeting a $1B+ orphan market with no approved therapies. The NEAT trial addresses prior design flaws, is 90% powered for statistical significance in 6-9 year-olds, and enjoys strong regulatory alignment. QNCX has sufficient cash through the NEAT readout, plans for platform expansion, and has a commercialization partnership with Option Care Health. Read the full article on Seeking Alpha
Analysis Article • Oct 07

Is Quince Therapeutics (NASDAQ:QNCX) Using Too Much Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Aug 20

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Summary Quince’s transformation is complete with the acquisition of EryDel in October 2023. The ongoing Phase 3 trial for the orphan disease Ataxia-Telangiectasia builds on the recently published teachings of EryDel’s earlier trial. Chances for success are high, with approval and multi-billion dollar potential around the corner after topline data next year. The company’s current market cap represents less than half the company’s cash level. Read the full article on Seeking Alpha
Analysis Article • Nov 21

Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Jul 27

Cortexyme to change name and ticker symbol next month

Alzheimer’s drug developer Cortexyme (NASDAQ:CRTX) announced on Wednesday that the company would change its corporate name and ticker symbol with effect from August. Accordingly, Cortexyme (CRTX) will be branded as Quince Therapeutics next month, and its ticker symbol on the Nasdaq Global Select Market will change to “QNCX” at the market open on Aug. 01. Coinciding with the change, Quince Therapeutics is expected to issue a press release detailing its growth strategy and plans for the development pipeline. In addition, Quince’s new corporate website and social media profiles on Twitter and LinkedIn will launch on the same day. Seeking Alpha contributor Terry Chrisomalis points out that San Francisco, California-based biotech is pursuing a market opportunity worth $17.7B with its Alzheimer's candidate COR588.
Seeking Alpha • Mar 01

Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment

COR588 is the second-generation lysine gingipain inhibitor which is being developed to treat Alzheimer's Disease and other P. gingivalis diseases. COR388, the first-generation lysine gingipain inhibitor, didn't achieve statistical significance in the entire Alzheimer's population, but did well in a prespecified group of patients with P. gingivalis. The global market opportunity for Alzheimer's Disease could reach $17.7 billion by 2025. COR388 is not being used towards Alzheimer's Disease, but Cortexyme is still developing it against other P. gingivalis diseases like periodontal disease and oral/head and neck squamous cell carcinoma.

Revenue & Expenses Breakdown

How Quince Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:QNCX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 260-331534
31 Dec 250-841535
30 Sep 250-571329
30 Jun 250-491425
31 Mar 250-611523
31 Dec 240-571819
30 Sep 240-531616
30 Jun 240-531713
31 Mar 240-301710
31 Dec 230-31159
30 Sep 230-28169
30 Jun 230-311610
31 Mar 230-422016
31 Dec 220-522525
30 Sep 220-703038
30 Jun 220-833349
31 Mar 220-883257
31 Dec 210-903061
30 Sep 210-872661
30 Jun 210-872364
31 Mar 210-832164
31 Dec 200-771861
30 Sep 200-691655
30 Jun 200-571347
31 Mar 200-481140
31 Dec 190-37930
30 Sep 190-28723
30 Jun 190-21517
31 Mar 190-15312
31 Dec 180-12210

Quality Earnings: QNCX is currently unprofitable.

Growing Profit Margin: QNCX is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: QNCX is unprofitable, but has reduced losses over the past 5 years at a rate of 12.5% per year.

Accelerating Growth: Unable to compare QNCX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: QNCX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).

Return on Equity

High ROE: QNCX has a negative Return on Equity (-210.8%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/11 16:20
End of Day Share Price 2026/06/11 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Quince Therapeutics, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Kumaraguru RajaBrookline Capital Markets
Sumant Satchidanand KulkarniCanaccord Genuity